{"id":"ak117-in-combination-with-ak112","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL5715933","moleculeType":null,"molecularWeight":"612.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AK117 is a bispecific antibody targeting PD-1 and LAG-3, while AK112 targets PD-L1 and TIM-3. Together, they block multiple inhibitory immune checkpoints on T cells, releasing brakes on anti-tumor immunity and promoting T-cell activation and proliferation. This dual-checkpoint blockade approach aims to overcome resistance to single-agent checkpoint inhibition.","oneSentence":"AK117 and AK112 are bispecific antibodies that simultaneously engage immune checkpoint pathways to enhance anti-tumor T-cell responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:29.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 evaluation)"}]},"trialDetails":[{"nctId":"NCT05227664","phase":"PHASE2","title":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-03-23","conditions":"Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer","enrollment":120},{"nctId":"NCT05229497","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-05-04","conditions":"Advanced Malignant Tumors","enrollment":154},{"nctId":"NCT05214482","phase":"PHASE1, PHASE2","title":"A Study of AK112 in Advanced Malignant Tumors","status":"COMPLETED","sponsor":"Akeso","startDate":"2022-01-22","conditions":"Advanced Malignant Tumors","enrollment":154},{"nctId":"NCT07264075","phase":"PHASE3","title":"Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN","status":"NOT_YET_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2026-01","conditions":"Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)","enrollment":780},{"nctId":"NCT06601335","phase":"PHASE3","title":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":510}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AK117 in combination with AK112","genericName":"AK117 in combination with AK112","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AK117 and AK112 are bispecific antibodies that simultaneously engage immune checkpoint pathways to enhance anti-tumor T-cell responses. Used for Advanced or metastatic solid tumors (Phase 3 evaluation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}